ARCT - Arcturus Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

437.5M

Cash

292M

Avg Qtr Burn

-4.525M

Short % of Float

19.59%

Insider Ownership

8.75%

Institutional Own.

90.49%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ARCT-154 Details COVID-19	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARCT-810 Details Ornithine transcarbmylase deficiency, Urea cycle disorder	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARCT-2138 Details Influenza	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARCT-032 Details Lung disease, Cystic fibrosis	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARCT-021 Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.